Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

NS5A inhibitor composition

A composition and compound technology, applied in the direction of antiviral agents, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve problems such as preclinical research in the early stage

Pending Publication Date: 2021-05-28
YICHANG HEC CHANGJIANG PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Prior art CN105693700B provides compounds (I), (II) and pharmaceutically acceptable salts thereof, which have good biological properties, but this prior art research is still in the early stage of preclinical research, in order to help The development of clinical research requires further research on the properties of the drug, and the search for drug salts and drug dosage forms suitable for human consumption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NS5A inhibitor composition
  • NS5A inhibitor composition
  • NS5A inhibitor composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0160] Compound III capsules were prepared according to the recipe shown below, and the dissolution rate was determined.

[0161] Preparation:

[0162] (1) The drug particle size D of compound III 50 =47.1μm, microcrystalline cellulose, mannitol, croscarmellose sodium, micropowder silica gel, magnesium stearate passed through a 60-mesh sieve;

[0163] (2) Weigh the components according to the prescription ratio:

[0164] Compound III: 29.27;

[0165] Microcrystalline cellulose: 22.24;

[0166] Mannitol: 44.49;

[0167] Croscarmellose sodium: 2.00;

[0168] Micropowder silica gel: 1.00;

[0169] Magnesium stearate: 1.00;

[0170] Total: 100.

[0171] (3) Mix the microcrystalline cellulose, mannitol, croscarmellose sodium and compound III in the prescribed amount for 20 minutes until uniform, to obtain a mixture;

[0172] (3) The magnesium stearate of the sieved prescription ratio added in the mixture, after total mixing 5min to evenly, is filled into 100mg specificatio...

Embodiment 2

[0175] Compound III capsules were prepared according to the recipe shown below, and the dissolution rate was determined.

[0176] Preparation:

[0177] (1) The drug particle size D of compound III 50 =35.9μm, microcrystalline cellulose, mannitol, croscarmellose sodium, micropowder silica gel, magnesium stearate passed through a 60-mesh sieve;

[0178] (2) Weigh the components according to the prescription ratio:

[0179] Compound III: 29.27;

[0180] Microcrystalline cellulose: 22.24;

[0181] Mannitol: 44.49;

[0182] Croscarmellose sodium: 2.00;

[0183] Micropowder silica gel: 1.00;

[0184] Magnesium stearate: 1.00;

[0185] Total: 100.

[0186] (3) Mix the microcrystalline cellulose, mannitol, croscarmellose sodium and compound III in the prescribed amount for 20 minutes until uniform, to obtain a mixture;

[0187] (3) The magnesium stearate of the sieved prescription ratio added in the mixture, after total mixing 5min to evenly, is filled into 100mg specificatio...

Embodiment 3

[0190] Compound III capsules were prepared according to the recipe shown below, and the dissolution rate was determined.

[0191] Preparation:

[0192](1) The drug particle size D of compound III 50 =22.5μm, microcrystalline cellulose, mannitol, croscarmellose sodium, micropowder silica gel, magnesium stearate passed through a 60-mesh sieve;

[0193] (2) Weigh the components according to the prescription ratio:

[0194] Compound III: 29.27;

[0195] Microcrystalline cellulose: 22.24;

[0196] Mannitol: 44.49;

[0197] Croscarmellose sodium: 2.00;

[0198] Micropowder silica gel: 1.00;

[0199] Magnesium stearate: 1.00;

[0200] Total: 100.

[0201] (3) Mix the microcrystalline cellulose, mannitol, croscarmellose sodium and compound III in the prescribed amount for 20 minutes until uniform, to obtain a mixture;

[0202] (3) The magnesium stearate of the sieved prescription ratio added in the mixture, after total mixing 5min to evenly, is filled into 100mg specification...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention provides a composition. The composition comprises a compound shown in a formula (I) or a formula (II) or a pharmaceutically acceptable salt thereof as an active ingredient, or a compound shown in a formula (III) or a formula (IV) as an active ingredient. The particle size of the active component satisfies the following condition: D50 is greater than or equal to 20 [mu]m and D50 is less than or equal to 50 [mu]m. The composition can be used for effectively treating the hepatitis C virus, and is high in safety and quick in effect.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a composition for treating hepatitis C and capsules thereof. Background technique [0002] Viral hepatitis C is a global infectious disease caused by hepatitis C virus (Hepatitis C virus, HCV). It progresses to chronic hepatitis, and 20 years after infection, about 5% to 15% develop liver cirrhosis, the annual incidence of liver cirrhosis decompensation is 3% to 4%, and 2% to 4% of liver cirrhosis patients develop liver cancer every year ( HCC), HCV is a serious hazard to the health and life of patients, and the symptoms of CHC patients are hidden, the diagnosis rate of HCV infection and the rate of antiviral treatment are low, there are many hidden sources of infection in the crowd, and it has become a serious social problem. and public health issues. [0003] According to the updated data of the World Health Organization (WHO) in April 2016, the global chronic HCV infection rate is ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4178A61K9/48A61K47/32A61K47/38A61K47/36A61K47/26A61K47/02A61P31/14
CPCA61K31/4178A61K9/4866A61K9/4858A61K9/485A61P31/14A61K2300/00
Inventor 欧金来郭朕谢洪明张英俊
Owner YICHANG HEC CHANGJIANG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com